You have read all your free articles, to continue reading subscribe to read the rest of this content.
Inficure Bio has signed an agreement with a publicly listed US biopharmaceutical company that develops drugs for several chronic and life-threatening diseases. “We will now begin testing the effects of their drug substances in our model. The company is world-leading in drug development, so thisAlready a subscriber Login You have…
Public-private partnerships are addressing the major challenges of microbial drug resistance. In 2016, a woman in the United States died from a bacterial strain resistant to 26 antibiotics. Recently, The Lancet reported on a dangerously resistant strain in China. The World Health OrganizAlready a subscriber Login You have read all your free articles, to continue reading subscribe to read…
Xbrane Biopharma and China Resource Pharmaceutical Group Limited have entered into a license agreement which gives CR Pharma exclusive rights to market and sell Spherotide (Triptorelin, a GnRH analogue in a parenteral depot formulation) in China. Swedish Xbrane will receive a license fee in high Already a subscriber Login You…
Earlier this summer Immunicum announced a corporate rebranding and name change to Mendus and most recently the company reported financing commitments totaling up to 250 million SEK. NLS asked Erik Manting, CEO, about what lies ahead. What opportunities do you have on the market for cancer immunotAlready a subscriber Login…
